Grant C C, Duggan A K, DeAngelis C
Division of General Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Pediatrics. 1995 Aug;96(2 Pt 1):224-9.
To determine the effectiveness of a single dose of prednisone administered by a parent to a child early in an asthma attack.
A randomized, double-blind, placebo-controlled, crossover study with children enrolled for 12 months (6 months prednisone, 6 months placebo).
A primary-care clinic and emergency department of an inner-city teaching hospital from March 1992 through May 1993.
Children 2 to 14 years of age enrolled in this clinic who had made two or more outpatient (emergency department or primary-care clinic) visits for acute asthma in the preceding year.
There were 204 eligible children, of whom 86 were contacted and enrolled; of these, 78 (91%) completed the study.
Capsules containing prednisone (2 mg/kg up to 60 mg) or placebo. Parents were instructed to give their child one capsule for an asthma attack that had not improved after a dose of the child's regular acute asthma medicine.
Parents were interviewed every 3 months. Computerized patient records and chart reviews were used to verify parent reports. Outcome measures were the numbers of outpatient visits and hospitalizations for treatment of acute asthma.
Neither the total number of attacks nor the number for which medicine was used differed significantly by arm of study. There was a larger number of attacks resulting in outpatient visits when children were in the group that received prednisone (1.1 +/- 0.59 versus 0.59 +/- 0.86). This trend was less pronounced but persisted when limited to attacks for which the medicine was given (0.58 +/- 0.99 versus 0.35 +/- 0.55). Neither the number of attacks resulting in admission nor the number of hospital days differed significantly by arm of study.
A single dose of prednisone available for use at home early in an asthma attack was associated with an increase in outpatient visits made for acute asthma. When prednisone was given for an attack, there was no reduction in outpatient visits. This intervention can not be recommended for children with asthma. These results should be confirmed in other pediatric populations.
确定在哮喘发作早期由家长给孩子单次服用泼尼松的有效性。
一项随机、双盲、安慰剂对照的交叉研究,儿童入组12个月(6个月服用泼尼松,6个月服用安慰剂)。
1992年3月至1993年5月期间市内一家教学医院的初级保健诊所和急诊科。
该诊所中2至14岁的儿童,他们在前一年因急性哮喘进行了两次或更多次门诊(急诊科或初级保健诊所)就诊。
有204名符合条件的儿童,其中86名被联系并纳入研究;这些儿童中,78名(91%)完成了研究。
含有泼尼松(2mg/kg,最大剂量60mg)或安慰剂的胶囊。家长被指示在孩子服用常规急性哮喘药物一剂后病情未改善的哮喘发作时给孩子服用一粒胶囊。
每3个月对家长进行一次访谈。使用计算机化的患者记录和病历审查来核实家长的报告。结果指标是急性哮喘治疗的门诊就诊次数和住院次数。
研究组间的发作总数或用药的发作次数均无显著差异。当儿童在接受泼尼松治疗的组时,因门诊就诊的发作次数较多(1.1±0.59对0.59±0.86)。当仅限于用药的发作时,这种趋势不太明显但仍然存在(0.58±0.99对0.35±0.55)。研究组间因住院的发作次数或住院天数均无显著差异。
在哮喘发作早期可在家中使用的单次剂量泼尼松与急性哮喘门诊就诊次数增加有关。当因发作给予泼尼松时,门诊就诊次数并未减少。不建议对哮喘儿童采用这种干预措施。这些结果应在其他儿科人群中得到证实。